Paris – Sanofi, the global pharmaceutical company, has announced a strategic collaboration with South Korea-based biotech ADEL to develop and potentially commercialize a novel experimental therapy for Alzheimer’s disease. The agreement is valued at $1.04 billion and includes upfront payments, milestone-based funding, and royalties on future sales.
Under the terms of the deal, ADEL will receive $80 million upfront, with additional payments contingent on clinical development milestones, regulatory approvals, and commercial performance. The partnership targets ADEL’s drug candidate, ADEL-Y01, an antibody therapy designed to block harmful forms of a protein implicated in Alzheimer’s disease. The therapy is currently in early-stage human trials in the United States.
“ADEL’s innovative approach to targeting tau acetylation provides a promising mechanism to address the underlying causes of Alzheimer’s disease,” said Erik Wallstroem, Global Head of Multiple Sclerosis, Neurology, and Gene Therapy Development at Sanofi.
In a related development, Sanofi also signed a separate collaboration with private biotech Dren Bio, valued at up to $1.7 billion, to advance therapies for autoimmune diseases, further expanding the company’s pipeline in high-unmet-need areas.
About Sanofi
Sanofi is a multinational biopharmaceutical company committed to advancing healthcare through research, development, and the delivery of innovative medicines. Its portfolio spans multiple therapeutic areas, including neurology, immunology, and rare diseases.
By